• Acorda Therapeutics Inc., of Hawthorne, N.Y., received U.S. Patent No. 11,010,828 titled "Sustained Release Aminopyridine Composition."

• Advanced Cell Technology Inc., of Marlborough, Mass., received U.S. Patent No. 7,893,315 for the company's single-blastomere technology.

• Agennix AG, of Planegg, Germany, received U.S. Patent No. 7,901,879 titled "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases."

• AlphaRx Inc., of Hong Kong, received a notice of allowance for its lead pain product candidate ARX8203.

• Angiochem Inc., of Montreal, received U.S. Patent No. 7,902,156, titled "Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier."

• Arena Pharmaceuticals, Inc., of San Diego, received U.S. Reissue Patent No. RE42,190 with claims to methods of identifying compounds that modulate the activity of the GPR119 receptor.

• Benitec Ltd., of Melbourne, Australia, received a re-examination certificate for U.S. Patent No. 6,573,099 titled "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene," which reinstates the patent.

• Ceapro Inc., of Edmonton, Alberta, received U.S. Patent No. 7,887,823 titled "Oat Extracts: Refining, Compositions and Methods of Use."

• Celsion Corp., of Columbia, Md., received U.S. Patent No. 7,901,709 for a new method of loading active agents such as doxorubicin or other active chemotherapy drugs into liposomes.